ABOS ▼ -69.4% - Acumen Pharmaceuticals, Inc.
$ABOS - Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
30-OCT-2026 07:00 AM ET
Share this post
More filings for $ABOS
ABOS ▲ +2.5% - Acumen Pharmaceuticals, Inc.Oct 26, 2026ABOS ▲ +4.7% - Acumen Pharmaceuticals, Inc.Oct 19, 2026ABOS ▲ +0.4% - Acumen Pharmaceuticals, Inc.Sep 10, 2026ABOS ▲ +5.8% - Acumen Pharmaceuticals, Inc.Sep 2, 2026
View full $ABOS filing history →💬 Comments
Loading comments…
Leave a comment